<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61910">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696136</url>
  </required_header>
  <id_info>
    <org_study_id>RDC-2010.01</org_study_id>
    <nct_id>NCT01696136</nct_id>
  </id_info>
  <brief_title>Multi-electrode PulmonarY Vein Isolation Versus Single Tip Wide Area Catheter Ablation for Paroxysmal Atrial Fibrillation (PAF)</brief_title>
  <acronym>MYSTIC-PAF</acronym>
  <official_title>Multi-electrode PulmonarY Vein Isolation Versus Single Tip Wide Area Catheter Ablation for PAF a Randomized Multinational Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>L.V.A. Boersma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R&amp;D Cardiologie</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MYSTIC_PAF trial investigates the differences between treatment with a single-tip
      catheter against a multielectrode catheter in cardiac ablation procedures in patients with
      paroxysmal atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Freedom of AF</measure>
    <time_frame>Month 3 after intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Is the patient free of Atrial Fibrillation, at month 3 after the ablation intervention, and not taking anti-arrhythmic drugs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AF-Ablation with Multi-electrode catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular AF-ablation with a multi-electrode ablation catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AF-Ablation with single-tip electrode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular AF-ablation with a regular single-tip ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac ablation for Atrial Fibrillation</intervention_name>
    <description>Cardiac ablation for Atrial Fibrillation</description>
    <arm_group_label>AF-Ablation with Multi-electrode catheter</arm_group_label>
    <arm_group_label>AF-Ablation with single-tip electrode</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of symptomatic paroxysmal atrial fibrillation defined as:

               -  Self-terminating AF with episodes lasting no more  than seven consecutive days
                  before spontaneous conversion back to sinus rhythm

               -  Documentation of one or more events with PAF tracings by ECG, event recordings,
                  pacemaker strips or monitor rhythm strips within the past year

               -  AF symptoms defined as the manifestation of any of the following:

                    -  Palpitations

                    -  Fatigue

                    -  Exertional dyspnea

                    -  Effort intolerance

          2. Age between 18 and 70

          3. Willingness, ability and commitment to participate in baseline and follow-up
             evaluations for the full length of the study

        Exclusion Criteria:

          1. Structural heart disease of clinical significance including:

               -  Previous cardiac surgery (excluding CABG)

               -  Symptoms of congestive heart failure including, but not limited to, NYHA Class
                  III or IV CHF and/or documented ejection fraction &lt; 40% measured by acceptable
                  cardiac testing

               -  Left atrial diameter of &gt; 50mm as measured in the parasternal long axis on
                  transthoracic echocardiogram

               -  Stable/unstable angina or ongoing myocardial ischemia

               -  Myocardial infarction (MI) within three months of enrollment

               -  Aortic or mitral valve disease &gt; Grade II

               -  Congenital heart disease (not including ASD or PFO without a right to left
                  shunt) where the underlying abnormality increases the risk of an ablative
                  procedure

               -  Prior ASD or PFO closure with a device using a percutaneous approach

               -  Hypertrophic cardiomyopathy (LV wall thickness &gt; 1.5 cm)

               -  Pulmonary hypertension (mean or systolic PA pressure &gt;50mm Hg on Doppler echo

          2. Prior ablation for arrhythmias other than AF within the past three months

          3. Prior left sided AF ablation

          4. Enrollment in any other ongoing arrhythmia study protocol Any ventricular
             tachyarrhythmias currently being treated where the arrhythmia or the management may
             interfere with this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>L.V.A. Boersma, MD PhD</last_name>
    <phone>+31-30-6099111</phone>
    <email>l.boersma@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3534CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.A.R. Bosschaert, MD</last_name>
      <phone>+31-30-6092278</phone>
      <email>m.bosschaert@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>L.V.A. Boersma, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 27, 2012</lastchanged_date>
  <firstreceived_date>September 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>R&amp;D Cardiologie</investigator_affiliation>
    <investigator_full_name>L.V.A. Boersma</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Ablation</keyword>
  <keyword>Multi-electrode catheter</keyword>
  <keyword>Single-tip catheter</keyword>
  <keyword>Holter</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
